Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients

Antiviral Therapy

Volumn 17, Issue 5, 2012, Pages 915-919

  Bastard, Jean Philippe ^a,b   Soulié, Cathia ^a,c   Fellahi, Soraya ^a,b   Haïm Boukobza, Stephanie ^a,c   Simon, Anne ^c   Katlama, Christine ^a,c   Calvez, Vincent ^a,c   Marcelin, Anne Geneviève ^a,c   Capeau, Jacqueline ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL TENON   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BODY MASS; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84865748268     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2093     Document Type: Article

References (15)

1. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010; 5:498-503.
2. Regidor DL, Detels R, Breen EC, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011; 25:303-314.
3. Baker JV, Neuhaus J, Duprez D, et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56:36-43.
4. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23:929-939.
5. Neuhaus J, Jacobs DR, Jr., Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
6. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
7. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-322.
8. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-273.
9. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-1127.
10. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
11. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
12. Haïm-Boukobza S, Morand-Joubert L, Flandre P, et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS 2011; 25:341-344.
13. Yim HC, Li JC, Lau JS, Lau AS. HIV-1 Tat dysregulation of lipopolysaccharide-induced cytokine responses: microbial interactions in HIV infection. AIDS 2009; 23:1473-1484.
14. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-1238.
15. Masiá M, Bernal E, Padilla S, et al. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2007; 195:167-171.